# Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

> **NCT00520845** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** celecoxib
- **DRUG:** Docetaxel
- **DRUG:** pemetrexed disodium
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00520845
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520845, "Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00520845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*